Unknown

Dataset Information

0

NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety.


ABSTRACT: A new treatment paradigm for hepatitis C is that the treatment must include an existing direct-acting antiviral agent, namely, a protease inhibitor (PI) combined with PEGylated interferon-? and ribavirin. The currently marketed PIs and PIs in clinical trials have different mechanisms of action. The development of new PIs aims for an improved safety profile and higher effectiveness. This article reviews NS3/4A protease inhibitors, focusing on major criteria such as their effectiveness and safety. Specific attention is paid to dosing regimens and adverse event profiles of PIs administered in clinical settings.

SUBMITTER: Bakulin I 

PROVIDER: S-EPMC4033290 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety.

Bakulin Igor I   Pasechnikov Victor V   Varlamicheva Anna A   Sannikova Irina I  

World journal of hepatology 20140501 5


A new treatment paradigm for hepatitis C is that the treatment must include an existing direct-acting antiviral agent, namely, a protease inhibitor (PI) combined with PEGylated interferon-α and ribavirin. The currently marketed PIs and PIs in clinical trials have different mechanisms of action. The development of new PIs aims for an improved safety profile and higher effectiveness. This article reviews NS3/4A protease inhibitors, focusing on major criteria such as their effectiveness and safety.  ...[more]

Similar Datasets

| S-EPMC4650141 | biostudies-literature
| S-EPMC3728351 | biostudies-literature
| S-EPMC7717897 | biostudies-literature
| S-EPMC3342569 | biostudies-literature
| S-EPMC2573085 | biostudies-other
| S-EPMC4027635 | biostudies-literature
| S-EPMC3406087 | biostudies-literature
| S-EPMC3974320 | biostudies-literature
| S-EPMC3586733 | biostudies-literature
| S-EPMC3185733 | biostudies-literature